• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Michael R. Hamblin, PhD

Associate Professor, Department of Dermatology, Harvard Medical School

Associate Chemist, Dermatology, Massachusetts General Hospital

Contact Info

Michael Hamblin
Massachusetts General Hospital
55 Fruit Street
Boston, MA, 02114
Mailstop: BAR 414
Phone: 617-726-6182
Fax: 617-726-8566
hamblin@helix.mgh.harvard.edu

Assistant

Andrea Johnston
Administrative Assistant
Dermatology
Massachusetts General Hospital
55 Fruit Street
Boston, MA, 02114
Phone: 617-726-1588
ajohnston2@partners.org

DF/HCC Program Affiliation

Gynecologic Cancers

Research Abstract

Photodynamic therapy is a relatively new and exciting approach for treating cancers and other diseases. Many new photosensitizers have been developed in recent years, but it is still not clear what is the basic mechanism of the tumor localizing effect, and hence the optimum structure and formulation of the photosensitizer for any particular application is uncertain.

My particular area of interest is in the preparation and investigation of macromolecular conjugates of photosensitizers. Large molecules have very different biodistribution and pharmacokinetics compared to the small molecules which are generally used as photosensitizers. In addition it may be possible to use conjugates of photosensitizers with specifically targeted macromolecules to cancer cells and other defined cells and organs. I am also interested in the use of PDT to generate long-term specific anti-tumor immunity in immunocompetent mouse tumor models, and its relation to specific PDT parameters.

Examples of the above approaches are,

(a) the use of monoclonal antibody photosensitizer conjugates directed towards tumor associated antigens to target metastatic ovarian and colorectal cancer.

(b) the use of conjugates with polyamino acids which can vary in size, charge and hydrophobicity and can therefore produce different pharmacokinetics, biodistributions and enhanced phototoxicities.

(c) targeting pathogenic bacteria which may produce wound infections or other diseases with polycationic photosensitizer conjugates

(d) the use of conjugates with serum proteins such as albumin and lipoproteins which could have improved tumor targeting properties and specificity for macrophage type cells.

(e) the use of macromolecular conjugates to direct photosensitizers to subcellular locations such as lysosomes, mitochondria and membranes, where they could either increase the cytotoxic effect, or conversely not kill the cell but induce it to express cytokines or growth factors which could be advantageous in such areas as wound healing.

Publications

View All Publications